文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).

作者信息

Golabi Pegah, Otgonsuren Munkhzul, de Avila Leyla, Sayiner Mehmet, Rafiq Nila, Younossi Zobair M

机构信息

Betty and Guy Beatty Center for Integrated Research, Inova Health System Center for Liver Disease, Department of Medicine, Inova Fair, Falls Church, VA.

出版信息

Medicine (Baltimore). 2018 Mar;97(13):e0214. doi: 10.1097/MD.0000000000010214.


DOI:10.1097/MD.0000000000010214
PMID:29595666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5895395/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Metabolic syndrome (MS) components are highly prevalent in NAFLD. Our aim is to assess the relationship of NAFLD and MS with long-term outcome of mortality.The Third National Health and Nutrition Examination Survey (NHANES) was utilized. NAFLD was diagnosed by ultrasound in the presence of hepatic steatosis and no other causes of chronic liver disease. History of MS and its components were obtained from self-reported NHANES questionnaires. Mortality was obtained from Mortality-Linkage File, through December 31, 2011. Chi-square test was used for categorical variables and Cox proportional models estimated hazard ratios with 95% confidence interval.NAFLD cohort (n = 3613) had a median age of 43 years, 73% white, and 50% male. NAFLD group with at least one MS condition was significantly older, had higher body mass index, more likely to have insulin resistance, and heart disease compared to NAFLD group without MS. Over 19-years of follow-up, 1039 people died. Compared to NAFLD patients without MS, presence of one MS component increased the risk of mortality at 8-year (2.6% vs 4.7%) and 16-year (6% vs 11.9%) (P < .001). After adjusting for socio-demographic factors, NAFLD with all MS components was associated with overall, cardiac and liver-mortality. Increased number of MS components was associated with lower survival (P < .0001).Patients with NAFLD and MS have higher mortality risk compared to NAFLD patients without MS. These NAFLD patients should be prioritized for the development of treatment regimens.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c3/5895395/bb43033b5d85/medi-97-e0214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c3/5895395/f6b0f3af583c/medi-97-e0214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c3/5895395/bb43033b5d85/medi-97-e0214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c3/5895395/f6b0f3af583c/medi-97-e0214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c3/5895395/bb43033b5d85/medi-97-e0214-g003.jpg

相似文献

[1]
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).

Medicine (Baltimore). 2018-3

[2]
Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States.

BMC Gastroenterol. 2019-4-16

[3]
In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.

Metabolism. 2012-9-19

[4]
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.

Metabolism. 2023-9

[5]
The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population.

J Clin Gastroenterol. 2017-2

[6]
The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States.

Liver Int. 2019-3-13

[7]
Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.

Vojnosanit Pregl. 2016-10

[8]
Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components.

Acta Diabetol. 2016-6

[9]
Relationship Between Handgrip Strength and Nonalcoholic Fatty Liver Disease: Nationwide Surveys.

Metab Syndr Relat Disord. 2018-8-21

[10]
Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease.

Front Endocrinol (Lausanne). 2021

引用本文的文献

[1]
Is nonalcoholic fatty liver disease associated with metabolic syndrome? An experience from a medical college of West Bengal, India.

J Family Med Prim Care. 2025-6

[2]
Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor.

J Clin Exp Hepatol. 2025

[3]
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.

J Clin Med. 2025-4-16

[4]
HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.

Clin Mol Hepatol. 2025-7

[5]
Association between SPISE and NAFLD in patients with type 2 diabetes.

Front Med (Lausanne). 2025-1-22

[6]
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.

Adv Ther. 2025-2

[7]
Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD.

JHEP Rep. 2024-8-22

[8]
Investigation of cardiovascular risk factors in diabetic and nondiabetic patients with nonalcoholic fatty liver disease.

J Res Med Sci. 2024-8-2

[9]
Epidemiology of metabolic dysfunction-associated steatotic liver disease.

Clin Mol Hepatol. 2025-2

[10]
Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease.

Gastro Hep Adv. 2022-4-8

本文引用的文献

[1]
Non-alcoholic fatty liver disease: A sign of systemic disease.

Metabolism. 2017-7

[2]
Non-alcoholic fatty liver disease and cardiovascular risk.

World J Gastrointest Pathophysiol. 2017-5-15

[3]
Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States.

Clin Diabetes. 2017-4

[4]
The epidemiology of non-alcoholic fatty liver disease.

Liver Int. 2017-1

[5]
Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.

BMJ Open Gastroenterol. 2016-8-16

[6]
Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.

Clin Res Hepatol Gastroenterol. 2017-2

[7]
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Hepatology. 2016-9-26

[8]
Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes.

Metabolism. 2016-7-1

[9]
The Natural Course of Non-Alcoholic Fatty Liver Disease.

Int J Mol Sci. 2016-5-20

[10]
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.

Clin Liver Dis. 2015-12-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索